Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.53B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.78M
Average 1.55M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$96.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Dianthus Therapeutics, Inc. NASDAQ:DNTH | $5.17B | $91.81 | Not rated | -343.0 | +113.08% |
Xencor, Inc. NASDAQ:XNCR | $2.78B | $37.09 | Not rated | -5.5 | +115.36% |
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | $46.25 | Overvalued | -59.7 | +84.88% |
MoonLake Immunotherapeutics NASDAQ:MLTX | $1.06B | $12.50 | Not rated | -5.4 | -16.04% |
Odyssey Therapeutics, Inc. NASDAQ:ODTX | $920.02M | $19.14 | Not rated | — | — |
Alumis Inc. Common Stock NASDAQ:ALMS | $724.84M | $5.60 | Not rated | -12.2 | -24.49% |
Attovia Therapeutics, Inc. NASDAQ:ATTO | $691.63M | $15.13 | Not rated | -15.9 | — |
Aclaris Therapeutics, Inc. NASDAQ:ACRS | $621.76M | $3.92 | Not rated | -8.2 | +35.74% |
Zura Bio Limited NASDAQ:ZURA | $119.44M | $1.24 | Not rated | -5.5 | -72.98% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $42.65M | $0.68 | Not rated | -4.0 | -68.79% |
Continue the stock analysis
Jump to another research area for this company.